APO Research
Talk to an analyst

APO RESEARCH · REPORT

Anti-Parkinson's Disease Drugs

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Anti-Parkinson's Disease Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

27 December 2025198 pages

Choose your research edition.

Industry ResearchAnti-Parkinson's Disease Drugs Industry Research Report 2026151 pages · $2,950 USDIndustry Growth & TrendsGlobal Anti-Parkinson's Disease Drugs Industry Growth and Trends Forecast to 2032122 pages · $3,450 USDMarket StructureGlobal Anti-Parkinson's Disease Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032198 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Anti-Parkinson's Disease Drugs Market Outlook and Growth Opportunities 2026214 pages · $4,250 USDMarket Analysis & ForecastGlobal Anti-Parkinson's Disease Drugs Market Analysis and Forecast 2026-2032215 pages · $4,950 USD

Market perspective

The global Anti-Parkinson's Disease Drugs market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for Anti-Parkinson's Disease Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Anti-Parkinson's Disease Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Anti-Parkinson's Disease Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Anti-Parkinson's Disease Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Anti-Parkinson's Disease Drugs include Zhejiang Huahai Pharmaceutical Co., Ltd., Tianjin Lisheng Pharmaceutical Co., Ltd., Ningbo Dahongying Pharmaceutical Co., Ltd., Jiangsu Tasly Diyi Pharmaceutical Co., Ltd., Hunan Zhongnan Pharmaceutical Co., Ltd., Hangzhou Guoguang Pharmaceutical Co., Ltd., Guangzhou Kanghe Pharmaceutical Co., Ltd., Fuzhou Haiwang Fuyao Pharmaceutical Co., Ltd. and Changzhou Kangpu Pharmaceutical Co., Ltd., among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Anti-Parkinson's Disease Drugs market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Anti-Parkinson's Disease Drugs and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Anti-Parkinson's Disease Drugs sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Anti-Parkinson's Disease Drugs market size, projected growth trends, production technologies, key applications, and end-use industries.

Anti-Parkinson's Disease Drugs Segment by Company

Zhejiang Huahai Pharmaceutical Co., Ltd.

Tianjin Lisheng Pharmaceutical Co., Ltd.

Ningbo Dahongying Pharmaceutical Co., Ltd.

Jiangsu Tasly Diyi Pharmaceutical Co., Ltd.

Hunan Zhongnan Pharmaceutical Co., Ltd.

Hangzhou Guoguang Pharmaceutical Co., Ltd.

Guangzhou Kanghe Pharmaceutical Co., Ltd.

Fuzhou Haiwang Fuyao Pharmaceutical Co., Ltd.

Changzhou Kangpu Pharmaceutical Co., Ltd.

Beijing Haiwang Zhongxin Pharmaceutical Co., Ltd.

Beijing Fuyuan Pharmaceutical Co., Ltd.

Valeant

Teva Pharmaceutical

Stada Arzneimittel

Roche Holding AG

Orion

Novartis

Merck

Lundbeck

Kyowa Kirin

GSK

Endo International plc

Desitin Arzneimittel

Boehringer Ingelheim

Bausch Health

Astellas Pharma

Apokyn

Akorn

Abbvie

Anti-Parkinson's Disease Drugs Segment by Type

Anticholinergics

Dopaminergics

Anti-Parkinson's Disease Drugs Segment by Application

Pharmacy

Hospital

Clinic

Other

Anti-Parkinson's Disease Drugs Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Anti-Parkinson's Disease Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Anti-Parkinson's Disease Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Anti-Parkinson's Disease Drugs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Anti-Parkinson's Disease Drugs market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Anti-Parkinson's Disease Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Anti-Parkinson's Disease Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of Anti-Parkinson's Disease Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Anti-Parkinson's Disease Drugs Industry Trends Table 2. Anti-Parkinson's Disease Drugs Industry Drivers Table 3. Anti-Parkinson's Disease Drugs Industry Opportunities and Challenges Table 4. Anti-Parkinson's Disease Drugs Industry Restraints Table 5. Global Anti-Parkinson's Disease Drugs Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global Anti-Parkinson's Disease Drugs Revenue Market Share by Manufacturers (2021-2026) Table 7. Global Anti-Parkinson's Disease Drugs Sales by Manufacturers (K Units) & (2021-2026) Table 8. Global Anti-Parkinson's Disease Drugs Sales Market Share by Manufacturers Table 9. Global Anti-Parkinson's Disease Drugs Average Sales Price (US$/Unit) of Manufacturers (2021-2026) Table 10. Global Anti-Parkinson's Disease Drugs Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global Anti-Parkinson's Disease Drugs Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global Anti-Parkinson's Disease Drugs Manufacturers, Product Type & Application Table 13. Global Anti-Parkinson's Disease Drugs Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global Anti-Parkinson's Disease Drugs by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of Anticholinergics Table 17. Major Manufacturers of Dopaminergics Table 18. Global Anti-Parkinson's Disease Drugs Sales by Type 2021 VS 2025 VS 2032 (K Units) Table 19. Global Anti-Parkinson's Disease Drugs Sales by Type (2021-2026) & (K Units) Table 20. Global Anti-Parkinson's Disease Drugs Sales by Type (2027-2032) & (K Units) Table 21. Global Anti-Parkinson's Disease Drugs Sales Market Share by Type (2021-2026) Table 22. Global Anti-Parkinson's Disease Drugs Sales Market Share by Type (2027-2032) Table 23. Global Anti-Parkinson's Disease Drugs Revenue by Type 2021 VS 2025 VS 2032 (K Units) Table 24. Global Anti-Parkinson's Disease Drugs Revenue by Type (2021-2026) & (K Units) Table 25. Global Anti-Parkinson's Disease Drugs Revenue by Type (2027-2032) & (K Units) Table 26. Global Anti-Parkinson's Disease Drugs Revenue Market Share by Type (2021-2026) Table 27. Global Anti-Parkinson's Disease Drugs Revenue Market Share by Type (2027-2032) Table 28. Major Manufacturers of Pharmacy Table 29. Major Manufacturers of Hospital Table 30. Major Manufacturers of Clinic Table 31. Major Manufacturers of Other Table 32. Global Anti-Parkinson's Disease Drugs Sales by Application 2021 VS 2025 VS 2032 (K Units) Table 33. Global Anti-Parkinson's Disease Drugs Sales by Application (2021-2026) & (K Units) Table 34. Global Anti-Parkinson's Disease Drugs Sales by Application (2027-2032) & (K Units) Table 35. Global Anti-Parkinson's Disease Drugs Sales Market Share by Application (2021-2026) Table 36. Global Anti-Parkinson's Disease Drugs Sales Market Share by Application (2027-2032) Table 37. Global Anti-Parkinson's Disease Drugs Revenue by Application 2021 VS 2025 VS 2032 (K Units) Table 38. Global Anti-Parkinson's Disease Drugs Revenue by Application (2021-2026) & (K Units) Table 39. Global Anti-Parkinson's Disease Drugs Revenue by Application (2027-2032) & (K Units) Table 40. Global Anti-Parkinson's Disease Drugs Revenue Market Share by Application (2021-2026) Table 41. Global Anti-Parkinson's Disease Drugs Revenue Market Share by Application (2027-2032) Table 42. Global Anti-Parkinson's Disease Drugs Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 43. Global Anti-Parkinson's Disease Drugs Sales by Region (2021-2026) & (K Units) Table 44. Global Anti-Parkinson's Disease Drugs Sales Market Share by Region (2021-2026) Table 45. Global Anti-Parkinson's Disease Drugs Sales Forecasted by Region (2027-2032) & (K Units) Table 46. Global Anti-Parkinson's Disease Drugs Sales Forecasted Market Share by Region (2027-2032) Table 47. North America Anti-Parkinson's Disease Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 48. North America Anti-Parkinson's Disease Drugs Sales by Country (2021-2026) & (K Units) Table 49. North America Anti-Parkinson's Disease Drugs Sales by Country (2027-2032) & (K Units) Table 50. Europe Anti-Parkinson's Disease Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 51. Europe Anti-Parkinson's Disease Drugs Sales by Country (2021-2026) & (K Units) Table 52. Europe Anti-Parkinson's Disease Drugs Sales by Country (2027-2032) & (K Units) Table 53. Asia Pacific Anti-Parkinson's Disease Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 54. Asia Pacific Anti-Parkinson's Disease Drugs Sales by Country (2021-2026) & (K Units) Table 55. Asia Pacific Anti-Parkinson's Disease Drugs Sales by Country (2027-2032) & (K Units) Table 56. South America, Middle East and Africa Anti-Parkinson's Disease Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 57. South America, Middle East and Africa Anti-Parkinson's Disease Drugs Sales by Country (2021-2026) & (K Units) Table 58. South America, Middle East and Africa Anti-Parkinson's Disease Drugs Sales by Country (2027-2032) & (K Units) Table 59. Global Anti-Parkinson's Disease Drugs Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 60. Global Anti-Parkinson's Disease Drugs Revenue by Region (2021-2026) & (US$ Million) Table 61. Global Anti-Parkinson's Disease Drugs Revenue by Region (2027-2032) & (US$ Million) Table 62. Global Anti-Parkinson's Disease Drugs Revenue Market Share by Region (2021-2026) Table 63. Global Anti-Parkinson's Disease Drugs Revenue Market Share by Region (2027-2032) Table 64. Zhejiang Huahai Pharmaceutical Co., Ltd. Company Information Table 65. Zhejiang Huahai Pharmaceutical Co., Ltd. Business Overview Table 66. Zhejiang Huahai Pharmaceutical Co., Ltd. Anti-Parkinson's Disease Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 67. Zhejiang Huahai Pharmaceutical Co., Ltd. Anti-Parkinson's Disease Drugs Product Portfolio Table 68. Zhejiang Huahai Pharmaceutical Co., Ltd. Recent Development Table 69. Tianjin Lisheng Pharmaceutical Co., Ltd. Company Information Table 70. Tianjin Lisheng Pharmaceutical Co., Ltd. Business Overview Table 71. Tianjin Lisheng Pharmaceutical Co., Ltd. Anti-Parkinson's Disease Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 72. Tianjin Lisheng Pharmaceutical Co., Ltd. Anti-Parkinson's Disease Drugs Product Portfolio Table 73. Tianjin Lisheng Pharmaceutical Co., Ltd. Recent Development Table 74. Ningbo Dahongying Pharmaceutical Co., Ltd. Company Information Table 75. Ningbo Dahongying Pharmaceutical Co., Ltd. Business Overview Table 76. Ningbo Dahongying Pharmaceutical Co., Ltd. Anti-Parkinson's Disease Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 77. Ningbo Dahongying Pharmaceutical Co., Ltd. Anti-Parkinson's Disease Drugs Product Portfolio Table 78. Ningbo Dahongying Pharmaceutical Co., Ltd. Recent Development Table 79. Jiangsu Tasly Diyi Pharmaceutical Co., Ltd. Company Information Table 80. Jiangsu Tasly Diyi Pharmaceutical Co., Ltd. Business Overview Table 81. Jiangsu Tasly Diyi Pharmaceutical Co., Ltd. Anti-Parkinson's Disease Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 82. Jiangsu Tasly Diyi Pharmaceutical Co., Ltd. Anti-Parkinson's Disease Drugs Product Portfolio Table 83. Jiangsu Tasly Diyi Pharmaceutical Co., Ltd. Recent Development Table 84. Hunan Zhongnan Pharmaceutical Co., Ltd. Company Information Table 85. Hunan Zhongnan Pharmaceutical Co., Ltd. Business Overview Table 86. Hunan Zhongnan Pharmaceutical Co., Ltd. Anti-Parkinson's Disease Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 87. Hunan Zhongnan Pharmaceutical Co., Ltd. Anti-Parkinson's Disease Drugs Product Portfolio Table 88. Hunan Zhongnan Pharmaceutical Co., Ltd. Recent Development Table 89. Hangzhou Guoguang Pharmaceutical Co., Ltd. Company Information Table 90. Hangzhou Guoguang Pharmaceutical Co., Ltd. Business Overview Table 91. Hangzhou Guoguang Pharmaceutical Co., Ltd. Anti-Parkinson's Disease Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 92. Hangzhou Guoguang Pharmaceutical Co., Ltd. Anti-Parkinson's Disease Drugs Product Portfolio Table 93. Hangzhou Guoguang Pharmaceutical Co., Ltd. Recent Development Table 94. Guangzhou Kanghe Pharmaceutical Co., Ltd. Company Information Table 95. Guangzhou Kanghe Pharmaceutical Co., Ltd. Business Overview Table 96. Guangzhou Kanghe Pharmaceutical Co., Ltd. Anti-Parkinson's Disease Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 97. Guangzhou Kanghe Pharmaceutical Co., Ltd. Anti-Parkinson's Disease Drugs Product Portfolio Table 98. Guangzhou Kanghe Pharmaceutical Co., Ltd. Recent Development Table 99. Fuzhou Haiwang Fuyao Pharmaceutical Co., Ltd. Company Information Table 100. Fuzhou Haiwang Fuyao Pharmaceutical Co., Ltd. Business Overview Table 101. Fuzhou Haiwang Fuyao Pharmaceutical Co., Ltd. Anti-Parkinson's Disease Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 102. Fuzhou Haiwang Fuyao Pharmaceutical Co., Ltd. Anti-Parkinson's Disease Drugs Product Portfolio Table 103. Fuzhou Haiwang Fuyao Pharmaceutical Co., Ltd. Recent Development Table 104. Changzhou Kangpu Pharmaceutical Co., Ltd. Company Information Table 105. Changzhou Kangpu Pharmaceutical Co., Ltd. Business Overview Table 106. Changzhou Kangpu Pharmaceutical Co., Ltd. Anti-Parkinson's Disease Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 107. Changzhou Kangpu Pharmaceutical Co., Ltd. Anti-Parkinson's Disease Drugs Product Portfolio Table 108. Changzhou Kangpu Pharmaceutical Co., Ltd. Recent Development Table 109. Beijing Haiwang Zhongxin Pharmaceutical Co., Ltd. Company Information Table 110. Beijing Haiwang Zhongxin Pharmaceutical Co., Ltd. Business Overview Table 111. Beijing Haiwang Zhongxin Pharmaceutical Co., Ltd. Anti-Parkinson's Disease Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 112. Beijing Haiwang Zhongxin Pharmaceutical Co., Ltd. Anti-Parkinson's Disease Drugs Product Portfolio Table 113. Beijing Haiwang Zhongxin Pharmaceutical Co., Ltd. Recent Development Table 114. Beijing Fuyuan Pharmaceutical Co., Ltd. Company Information Table 115. Beijing Fuyuan Pharmaceutical Co., Ltd. Business Overview Table 116. Beijing Fuyuan Pharmaceutical Co., Ltd. Anti-Parkinson's Disease Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 117. Beijing Fuyuan Pharmaceutical Co., Ltd. Anti-Parkinson's Disease Drugs Product Portfolio Table 118. Beijing Fuyuan Pharmaceutical Co., Ltd. Recent Development Table 119. Valeant Company Information Table 120. Valeant Business Overview Table 121. Valeant Anti-Parkinson's Disease Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 122. Valeant Anti-Parkinson's Disease Drugs Product Portfolio Table 123. Valeant Recent Development Table 124. Teva Pharmaceutical Company Information Table 125. Teva Pharmaceutical Business Overview Table 126. Teva Pharmaceutical Anti-Parkinson's Disease Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 127. Teva Pharmaceutical Anti-Parkinson's Disease Drugs Product Portfolio Table 128. Teva Pharmaceutical Recent Development Table 129. Stada Arzneimittel Company Information Table 130. Stada Arzneimittel Business Overview Table 131. Stada Arzneimittel Anti-Parkinson's Disease Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 132. Stada Arzneimittel Anti-Parkinson's Disease Drugs Product Portfolio Table 133. Stada Arzneimittel Recent Development Table 134. Roche Holding AG Company Information Table 135. Roche Holding AG Business Overview Table 136. Roche Holding AG Anti-Parkinson's Disease Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 137. Roche Holding AG Anti-Parkinson's Disease Drugs Product Portfolio Table 138. Roche Holding AG Recent Development Table 139. Orion Company Information Table 140. Orion Business Overview Table 141. Orion Anti-Parkinson's Disease Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 142. Orion Anti-Parkinson's Disease Drugs Product Portfolio Table 143. Orion Recent Development Table 144. Novartis Company Information Table 145. Novartis Business Overview Table 146. Novartis Anti-Parkinson's Disease Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 147. Novartis Anti-Parkinson's Disease Drugs Product Portfolio Table 148. Novartis Recent Development Table 149. Merck Company Information Table 150. Merck Business Overview Table 151. Merck Anti-Parkinson's Disease Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 152. Merck Anti-Parkinson's Disease Drugs Product Portfolio Table 153. Merck Recent Development Table 154. Lundbeck Company Information Table 155. Lundbeck Business Overview Table 156. Lundbeck Anti-Parkinson's Disease Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 157. Lundbeck Anti-Parkinson's Disease Drugs Product Portfolio Table 158. Lundbeck Recent Development Table 159. Kyowa Kirin Company Information Table 160. Kyowa Kirin Business Overview Table 161. Kyowa Kirin Anti-Parkinson's Disease Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 162. Kyowa Kirin Anti-Parkinson's Disease Drugs Product Portfolio Table 163. Kyowa Kirin Recent Development Table 164. GSK Company Information Table 165. GSK Business Overview Table 166. GSK Anti-Parkinson's Disease Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 167. GSK Anti-Parkinson's Disease Drugs Product Portfolio Table 168. GSK Recent Development Table 169. Endo International plc Company Information Table 170. Endo International plc Business Overview Table 171. Endo International plc Anti-Parkinson's Disease Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 172. Endo International plc Anti-Parkinson's Disease Drugs Product Portfolio Table 173. Endo International plc Recent Development Table 174. Desitin Arzneimittel Company Information Table 175. Desitin Arzneimittel Business Overview Table 176. Desitin Arzneimittel Anti-Parkinson's Disease Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 177. Desitin Arzneimittel Anti-Parkinson's Disease Drugs Product Portfolio Table 178. Desitin Arzneimittel Recent Development Table 179. Boehringer Ingelheim Company Information Table 180. Boehringer Ingelheim Business Overview Table 181. Boehringer Ingelheim Anti-Parkinson's Disease Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 182. Boehringer Ingelheim Anti-Parkinson's Disease Drugs Product Portfolio Table 183. Boehringer Ingelheim Recent Development Table 184. Bausch Health Company Information Table 185. Bausch Health Business Overview Table 186. Bausch Health Anti-Parkinson's Disease Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 187. Bausch Health Anti-Parkinson's Disease Drugs Product Portfolio Table 188. Bausch Health Recent Development Table 189. Astellas Pharma Company Information Table 190. Astellas Pharma Business Overview Table 191. Astellas Pharma Anti-Parkinson's Disease Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 192. Astellas Pharma Anti-Parkinson's Disease Drugs Product Portfolio Table 193. Astellas Pharma Recent Development Table 194. Apokyn Company Information Table 195. Apokyn Business Overview Table 196. Apokyn Anti-Parkinson's Disease Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 197. Apokyn Anti-Parkinson's Disease Drugs Product Portfolio Table 198. Apokyn Recent Development Table 199. Akorn Company Information Table 200. Akorn Business Overview Table 201. Akorn Anti-Parkinson's Disease Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 202. Akorn Anti-Parkinson's Disease Drugs Product Portfolio Table 203. Akorn Recent Development Table 204. Abbvie Company Information Table 205. Abbvie Business Overview Table 206. Abbvie Anti-Parkinson's Disease Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 207. Abbvie Anti-Parkinson's Disease Drugs Product Portfolio Table 208. Abbvie Recent Development Table 209. Key Raw Materials Table 210. Raw Materials Key Suppliers Table 211. Anti-Parkinson's Disease Drugs Distributors List Table 212. Anti-Parkinson's Disease Drugs Customers List Table 213. Research Programs/Design for This Report Table 214. Authors List of This Report Table 215. Secondary Sources Table 216. Primary Sources List of Figures Figure 1. Anti-Parkinson's Disease Drugs Product Image Figure 2. Global Anti-Parkinson's Disease Drugs Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Anti-Parkinson's Disease Drugs Market Size (2021-2032) & (US$ Million) Figure 4. Global Anti-Parkinson's Disease Drugs Sales (2021-2032) & (K Units) Figure 5. Global Anti-Parkinson's Disease Drugs Average Price (US$/Unit) & (2021-2032) Figure 6. Global Top 5 and 10 Anti-Parkinson's Disease Drugs Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. Anticholinergics Image Figure 9. Dopaminergics Image Figure 10. Global Anti-Parkinson's Disease Drugs Sales by Type (2021 VS 2025 VS 2032) & (K Units) Figure 11. Global Anti-Parkinson's Disease Drugs Sales Market Share 2021 VS 2025 VS 2032 Figure 12. Global Anti-Parkinson's Disease Drugs Sales Market Share by Type (2021-2032) Figure 13. Global Anti-Parkinson's Disease Drugs Revenue by Type (2021 VS 2025 VS 2032) & (K Units) Figure 14. Global Anti-Parkinson's Disease Drugs Revenue Market Share 2021 VS 2025 VS 2032 Figure 15. Global Anti-Parkinson's Disease Drugs Revenue Market Share by Type (2021-2032) Figure 16. Pharmacy Image Figure 17. Hospital Image Figure 18. Clinic Image Figure 19. Other Image Figure 20. Global Anti-Parkinson's Disease Drugs Sales by Application (2021 VS 2025 VS 2032) & (K Units) Figure 21. Global Anti-Parkinson's Disease Drugs Sales Market Share 2021 VS 2025 VS 2032 Figure 22. Global Anti-Parkinson's Disease Drugs Sales Market Share by Application (2021-2032) Figure 23. Global Anti-Parkinson's Disease Drugs Revenue by Application (2021 VS 2025 VS 2032) & (K Units) Figure 24. Global Anti-Parkinson's Disease Drugs Revenue Market Share 2021 VS 2025 VS 2032 Figure 25. Global Anti-Parkinson's Disease Drugs Revenue Market Share by Application (2021-2032) Figure 26. North America Anti-Parkinson's Disease Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 27. North America Anti-Parkinson's Disease Drugs Sales Market Share by Country (2021-2032) Figure 28. U.S. Anti-Parkinson's Disease Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 29. Canada Anti-Parkinson's Disease Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 30. Mexico Anti-Parkinson's Disease Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 31. Europe Anti-Parkinson's Disease Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 32. Europe Anti-Parkinson's Disease Drugs Sales Market Share by Country (2021-2032) Figure 33. Germany Anti-Parkinson's Disease Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 34. France Anti-Parkinson's Disease Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 35. U.K. Anti-Parkinson's Disease Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 36. Italy Anti-Parkinson's Disease Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 37. Netherlands Anti-Parkinson's Disease Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 38. Asia Pacific Anti-Parkinson's Disease Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 39. Asia Pacific Anti-Parkinson's Disease Drugs Sales Market Share by Country (2021-2032) Figure 40. China Anti-Parkinson's Disease Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 41. Japan Anti-Parkinson's Disease Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 42. South Korea Anti-Parkinson's Disease Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 43. Southeast Asia Anti-Parkinson's Disease Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 44. India Anti-Parkinson's Disease Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 45. Australia Anti-Parkinson's Disease Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 46. South America, Middle East and Africa Anti-Parkinson's Disease Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 47. South America, Middle East and Africa Anti-Parkinson's Disease Drugs Sales Market Share by Country (2021-2032) Figure 48. Brazil Anti-Parkinson's Disease Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 49. South Africa Anti-Parkinson's Disease Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 50. Saudi Arabia Anti-Parkinson's Disease Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 51. Turkey Anti-Parkinson's Disease Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 52. Argentina Anti-Parkinson's Disease Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 53. UAE Anti-Parkinson's Disease Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 54. Egypt Anti-Parkinson's Disease Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 55. Chile Anti-Parkinson's Disease Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 56. Global Anti-Parkinson's Disease Drugs Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 57. Global Anti-Parkinson's Disease Drugs Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 58. North America Anti-Parkinson's Disease Drugs Revenue (2021-2032) & (US$ Million) Figure 59. North America Anti-Parkinson's Disease Drugs Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 60. Europe Anti-Parkinson's Disease Drugs Revenue (2021-2032) & (US$ Million) Figure 61. Europe Anti-Parkinson's Disease Drugs Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 62. Asia-Pacific Anti-Parkinson's Disease Drugs Revenue (2021-2032) & (US$ Million) Figure 63. Asia-Pacific Anti-Parkinson's Disease Drugs Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 64. South America, Middle East and Africa Anti-Parkinson's Disease Drugs Revenue (2021-2032) & (US$ Million) Figure 65. South America, Middle East and Africa Anti-Parkinson's Disease Drugs Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 66. Anti-Parkinson's Disease Drugs Value Chain Figure 67. Manufacturing Cost Structure Figure 68. Anti-Parkinson's Disease Drugs Production Mode & Process Figure 69. Direct Comparison with Distribution Share Figure 70. Distributors Profiles Figure 71. Years Considered Figure 72. Research Process Figure 73. Key Executives Interviewed

Scope & coverage.

Types
  • Anticholinergics
  • Dopaminergics
Applications
  • Pharmacy
  • Hospital
  • Clinic
  • Other
Companies covered
  • Zhejiang Huahai Pharmaceutical Co., Ltd.
  • Tianjin Lisheng Pharmaceutical Co., Ltd.
  • Ningbo Dahongying Pharmaceutical Co., Ltd.
  • Jiangsu Tasly Diyi Pharmaceutical Co., Ltd.
  • Hunan Zhongnan Pharmaceutical Co., Ltd.
  • Hangzhou Guoguang Pharmaceutical Co., Ltd.
  • Guangzhou Kanghe Pharmaceutical Co., Ltd.
  • Fuzhou Haiwang Fuyao Pharmaceutical Co., Ltd.
  • Changzhou Kangpu Pharmaceutical Co., Ltd.
  • Beijing Haiwang Zhongxin Pharmaceutical Co., Ltd.
  • Beijing Fuyuan Pharmaceutical Co., Ltd.
  • Valeant
  • Teva Pharmaceutical
  • Stada Arzneimittel
  • Roche Holding AG
  • Orion
  • Novartis
  • Merck
  • Lundbeck
  • Kyowa Kirin
  • GSK
  • Endo International plc
  • Desitin Arzneimittel
  • Boehringer Ingelheim
  • Bausch Health
  • Astellas Pharma
  • Apokyn
  • Akorn
  • Abbvie

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Anti-Parkinson's Disease Drugs Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Anti-Parkinson's Disease Drugs Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global Anti-Parkinson's Disease Drugs Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global Anti-Parkinson's Disease Drugs Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global Anti-Parkinson's Disease Drugs Market Dynamics
  1. 2.1 Anti-Parkinson's Disease Drugs Industry Trends
  2. 2.2 Anti-Parkinson's Disease Drugs Industry Drivers
  3. 2.3 Anti-Parkinson's Disease Drugs Industry Opportunities and Challenges
  4. 2.4 Anti-Parkinson's Disease Drugs Industry Restraints
3 Anti-Parkinson's Disease Drugs Market by Manufacturers
  1. 3.1 Global Anti-Parkinson's Disease Drugs Revenue by Manufacturers (2021-2026)
  2. 3.2 Global Anti-Parkinson's Disease Drugs Sales by Manufacturers (2021-2026)
  3. 3.3 Global Anti-Parkinson's Disease Drugs Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global Anti-Parkinson's Disease Drugs Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Anti-Parkinson's Disease Drugs Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global Anti-Parkinson's Disease Drugs Manufacturers, Product Type & Application
  7. 3.7 Global Anti-Parkinson's Disease Drugs Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Anti-Parkinson's Disease Drugs Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Anti-Parkinson's Disease Drugs Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Anti-Parkinson's Disease Drugs Tier 1, Tier 2, and Tier 3
4 Anti-Parkinson's Disease Drugs Market by Type
  1. 4.1 Anti-Parkinson's Disease Drugs Type Introduction
  2. 4.1.1 Anticholinergics
  3. 4.1.2 Dopaminergics
  4. 4.2 Global Anti-Parkinson's Disease Drugs Sales by Type
  5. 4.2.1 Global Anti-Parkinson's Disease Drugs Sales by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Anti-Parkinson's Disease Drugs Sales by Type (2021-2032)
  7. 4.2.3 Global Anti-Parkinson's Disease Drugs Sales Market Share by Type (2021-2032)
  8. 4.3 Global Anti-Parkinson's Disease Drugs Revenue by Type
  9. 4.3.1 Global Anti-Parkinson's Disease Drugs Revenue by Type (2021 VS 2025 VS 2032)
  10. 4.3.2 Global Anti-Parkinson's Disease Drugs Revenue by Type (2021-2032)
  11. 4.3.3 Global Anti-Parkinson's Disease Drugs Revenue Market Share by Type (2021-2032)
5 Anti-Parkinson's Disease Drugs Market by Application
  1. 5.1 Anti-Parkinson's Disease Drugs Application Introduction
  2. 5.1.1 Pharmacy
  3. 5.1.2 Hospital
  4. 5.1.3 Clinic
  5. 5.1.4 Other
  6. 5.2 Global Anti-Parkinson's Disease Drugs Sales by Application
  7. 5.2.1 Global Anti-Parkinson's Disease Drugs Sales by Application (2021 VS 2025 VS 2032)
  8. 5.2.2 Global Anti-Parkinson's Disease Drugs Sales by Application (2021-2032)
  9. 5.2.3 Global Anti-Parkinson's Disease Drugs Sales Market Share by Application (2021-2032)
  10. 5.3 Global Anti-Parkinson's Disease Drugs Revenue by Application
  11. 5.3.1 Global Anti-Parkinson's Disease Drugs Revenue by Application (2021 VS 2025 VS 2032)
  12. 5.3.2 Global Anti-Parkinson's Disease Drugs Revenue by Application (2021-2032)
  13. 5.3.3 Global Anti-Parkinson's Disease Drugs Revenue Market Share by Application (2021-2032)
6 Global Anti-Parkinson's Disease Drugs Sales by Region
  1. 6.1 Global Anti-Parkinson's Disease Drugs Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Anti-Parkinson's Disease Drugs Sales by Region (2021-2032)
  3. 6.2.1 Global Anti-Parkinson's Disease Drugs Sales by Region (2021-2026)
  4. 6.2.2 Global Anti-Parkinson's Disease Drugs Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Anti-Parkinson's Disease Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America Anti-Parkinson's Disease Drugs Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe Anti-Parkinson's Disease Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe Anti-Parkinson's Disease Drugs Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific Anti-Parkinson's Disease Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific Anti-Parkinson's Disease Drugs Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa Anti-Parkinson's Disease Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa Anti-Parkinson's Disease Drugs Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global Anti-Parkinson's Disease Drugs Revenue by Region
  1. 7.1 Global Anti-Parkinson's Disease Drugs Revenue by Region
  2. 7.1.1 Global Anti-Parkinson's Disease Drugs Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global Anti-Parkinson's Disease Drugs Revenue by Region (2021-2026)
  4. 7.1.3 Global Anti-Parkinson's Disease Drugs Revenue by Region (2027-2032)
  5. 7.1.4 Global Anti-Parkinson's Disease Drugs Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America Anti-Parkinson's Disease Drugs Revenue (2021-2032)
  8. 7.2.2 North America Anti-Parkinson's Disease Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe Anti-Parkinson's Disease Drugs Revenue (2021-2032)
  11. 7.3.2 Europe Anti-Parkinson's Disease Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific Anti-Parkinson's Disease Drugs Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific Anti-Parkinson's Disease Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa Anti-Parkinson's Disease Drugs Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa Anti-Parkinson's Disease Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 Zhejiang Huahai Pharmaceutical Co., Ltd.
  2. 8.1.1 Zhejiang Huahai Pharmaceutical Co., Ltd. Company Information
  3. 8.1.2 Zhejiang Huahai Pharmaceutical Co., Ltd. Business Overview
  4. 8.1.3 Zhejiang Huahai Pharmaceutical Co., Ltd. Anti-Parkinson's Disease Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Zhejiang Huahai Pharmaceutical Co., Ltd. Anti-Parkinson's Disease Drugs Product Portfolio
  6. 8.1.5 Zhejiang Huahai Pharmaceutical Co., Ltd. Recent Developments
  7. 8.2 Tianjin Lisheng Pharmaceutical Co., Ltd.
  8. 8.2.1 Tianjin Lisheng Pharmaceutical Co., Ltd. Company Information
  9. 8.2.2 Tianjin Lisheng Pharmaceutical Co., Ltd. Business Overview
  10. 8.2.3 Tianjin Lisheng Pharmaceutical Co., Ltd. Anti-Parkinson's Disease Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Tianjin Lisheng Pharmaceutical Co., Ltd. Anti-Parkinson's Disease Drugs Product Portfolio
  12. 8.2.5 Tianjin Lisheng Pharmaceutical Co., Ltd. Recent Developments
  13. 8.3 Ningbo Dahongying Pharmaceutical Co., Ltd.
  14. 8.3.1 Ningbo Dahongying Pharmaceutical Co., Ltd. Company Information
  15. 8.3.2 Ningbo Dahongying Pharmaceutical Co., Ltd. Business Overview
  16. 8.3.3 Ningbo Dahongying Pharmaceutical Co., Ltd. Anti-Parkinson's Disease Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Ningbo Dahongying Pharmaceutical Co., Ltd. Anti-Parkinson's Disease Drugs Product Portfolio
  18. 8.3.5 Ningbo Dahongying Pharmaceutical Co., Ltd. Recent Developments
  19. 8.4 Jiangsu Tasly Diyi Pharmaceutical Co., Ltd.
  20. 8.4.1 Jiangsu Tasly Diyi Pharmaceutical Co., Ltd. Company Information
  21. 8.4.2 Jiangsu Tasly Diyi Pharmaceutical Co., Ltd. Business Overview
  22. 8.4.3 Jiangsu Tasly Diyi Pharmaceutical Co., Ltd. Anti-Parkinson's Disease Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Jiangsu Tasly Diyi Pharmaceutical Co., Ltd. Anti-Parkinson's Disease Drugs Product Portfolio
  24. 8.4.5 Jiangsu Tasly Diyi Pharmaceutical Co., Ltd. Recent Developments
  25. 8.5 Hunan Zhongnan Pharmaceutical Co., Ltd.
  26. 8.5.1 Hunan Zhongnan Pharmaceutical Co., Ltd. Company Information
  27. 8.5.2 Hunan Zhongnan Pharmaceutical Co., Ltd. Business Overview
  28. 8.5.3 Hunan Zhongnan Pharmaceutical Co., Ltd. Anti-Parkinson's Disease Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Hunan Zhongnan Pharmaceutical Co., Ltd. Anti-Parkinson's Disease Drugs Product Portfolio
  30. 8.5.5 Hunan Zhongnan Pharmaceutical Co., Ltd. Recent Developments
  31. 8.6 Hangzhou Guoguang Pharmaceutical Co., Ltd.
  32. 8.6.1 Hangzhou Guoguang Pharmaceutical Co., Ltd. Company Information
  33. 8.6.2 Hangzhou Guoguang Pharmaceutical Co., Ltd. Business Overview
  34. 8.6.3 Hangzhou Guoguang Pharmaceutical Co., Ltd. Anti-Parkinson's Disease Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Hangzhou Guoguang Pharmaceutical Co., Ltd. Anti-Parkinson's Disease Drugs Product Portfolio
  36. 8.6.5 Hangzhou Guoguang Pharmaceutical Co., Ltd. Recent Developments
  37. 8.7 Guangzhou Kanghe Pharmaceutical Co., Ltd.
  38. 8.7.1 Guangzhou Kanghe Pharmaceutical Co., Ltd. Company Information
  39. 8.7.2 Guangzhou Kanghe Pharmaceutical Co., Ltd. Business Overview
  40. 8.7.3 Guangzhou Kanghe Pharmaceutical Co., Ltd. Anti-Parkinson's Disease Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Guangzhou Kanghe Pharmaceutical Co., Ltd. Anti-Parkinson's Disease Drugs Product Portfolio
  42. 8.7.5 Guangzhou Kanghe Pharmaceutical Co., Ltd. Recent Developments
  43. 8.8 Fuzhou Haiwang Fuyao Pharmaceutical Co., Ltd.
  44. 8.8.1 Fuzhou Haiwang Fuyao Pharmaceutical Co., Ltd. Company Information
  45. 8.8.2 Fuzhou Haiwang Fuyao Pharmaceutical Co., Ltd. Business Overview
  46. 8.8.3 Fuzhou Haiwang Fuyao Pharmaceutical Co., Ltd. Anti-Parkinson's Disease Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Fuzhou Haiwang Fuyao Pharmaceutical Co., Ltd. Anti-Parkinson's Disease Drugs Product Portfolio
  48. 8.8.5 Fuzhou Haiwang Fuyao Pharmaceutical Co., Ltd. Recent Developments
  49. 8.9 Changzhou Kangpu Pharmaceutical Co., Ltd.
  50. 8.9.1 Changzhou Kangpu Pharmaceutical Co., Ltd. Company Information
  51. 8.9.2 Changzhou Kangpu Pharmaceutical Co., Ltd. Business Overview
  52. 8.9.3 Changzhou Kangpu Pharmaceutical Co., Ltd. Anti-Parkinson's Disease Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Changzhou Kangpu Pharmaceutical Co., Ltd. Anti-Parkinson's Disease Drugs Product Portfolio
  54. 8.9.5 Changzhou Kangpu Pharmaceutical Co., Ltd. Recent Developments
  55. 8.10 Beijing Haiwang Zhongxin Pharmaceutical Co., Ltd.
  56. 8.10.1 Beijing Haiwang Zhongxin Pharmaceutical Co., Ltd. Company Information
  57. 8.10.2 Beijing Haiwang Zhongxin Pharmaceutical Co., Ltd. Business Overview
  58. 8.10.3 Beijing Haiwang Zhongxin Pharmaceutical Co., Ltd. Anti-Parkinson's Disease Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Beijing Haiwang Zhongxin Pharmaceutical Co., Ltd. Anti-Parkinson's Disease Drugs Product Portfolio
  60. 8.10.5 Beijing Haiwang Zhongxin Pharmaceutical Co., Ltd. Recent Developments
  61. 8.11 Beijing Fuyuan Pharmaceutical Co., Ltd.
  62. 8.11.1 Beijing Fuyuan Pharmaceutical Co., Ltd. Company Information
  63. 8.11.2 Beijing Fuyuan Pharmaceutical Co., Ltd. Business Overview
  64. 8.11.3 Beijing Fuyuan Pharmaceutical Co., Ltd. Anti-Parkinson's Disease Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Beijing Fuyuan Pharmaceutical Co., Ltd. Anti-Parkinson's Disease Drugs Product Portfolio
  66. 8.11.5 Beijing Fuyuan Pharmaceutical Co., Ltd. Recent Developments
  67. 8.12 Valeant
  68. 8.12.1 Valeant Company Information
  69. 8.12.2 Valeant Business Overview
  70. 8.12.3 Valeant Anti-Parkinson's Disease Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Valeant Anti-Parkinson's Disease Drugs Product Portfolio
  72. 8.12.5 Valeant Recent Developments
  73. 8.13 Teva Pharmaceutical
  74. 8.13.1 Teva Pharmaceutical Company Information
  75. 8.13.2 Teva Pharmaceutical Business Overview
  76. 8.13.3 Teva Pharmaceutical Anti-Parkinson's Disease Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  77. 8.13.4 Teva Pharmaceutical Anti-Parkinson's Disease Drugs Product Portfolio
  78. 8.13.5 Teva Pharmaceutical Recent Developments
  79. 8.14 Stada Arzneimittel
  80. 8.14.1 Stada Arzneimittel Company Information
  81. 8.14.2 Stada Arzneimittel Business Overview
  82. 8.14.3 Stada Arzneimittel Anti-Parkinson's Disease Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  83. 8.14.4 Stada Arzneimittel Anti-Parkinson's Disease Drugs Product Portfolio
  84. 8.14.5 Stada Arzneimittel Recent Developments
  85. 8.15 Roche Holding AG
  86. 8.15.1 Roche Holding AG Company Information
  87. 8.15.2 Roche Holding AG Business Overview
  88. 8.15.3 Roche Holding AG Anti-Parkinson's Disease Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  89. 8.15.4 Roche Holding AG Anti-Parkinson's Disease Drugs Product Portfolio
  90. 8.15.5 Roche Holding AG Recent Developments
  91. 8.16 Orion
  92. 8.16.1 Orion Company Information
  93. 8.16.2 Orion Business Overview
  94. 8.16.3 Orion Anti-Parkinson's Disease Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  95. 8.16.4 Orion Anti-Parkinson's Disease Drugs Product Portfolio
  96. 8.16.5 Orion Recent Developments
  97. 8.17 Novartis
  98. 8.17.1 Novartis Company Information
  99. 8.17.2 Novartis Business Overview
  100. 8.17.3 Novartis Anti-Parkinson's Disease Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  101. 8.17.4 Novartis Anti-Parkinson's Disease Drugs Product Portfolio
  102. 8.17.5 Novartis Recent Developments
  103. 8.18 Merck
  104. 8.18.1 Merck Company Information
  105. 8.18.2 Merck Business Overview
  106. 8.18.3 Merck Anti-Parkinson's Disease Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  107. 8.18.4 Merck Anti-Parkinson's Disease Drugs Product Portfolio
  108. 8.18.5 Merck Recent Developments
  109. 8.19 Lundbeck
  110. 8.19.1 Lundbeck Company Information
  111. 8.19.2 Lundbeck Business Overview
  112. 8.19.3 Lundbeck Anti-Parkinson's Disease Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  113. 8.19.4 Lundbeck Anti-Parkinson's Disease Drugs Product Portfolio
  114. 8.19.5 Lundbeck Recent Developments
  115. 8.20 Kyowa Kirin
  116. 8.20.1 Kyowa Kirin Company Information
  117. 8.20.2 Kyowa Kirin Business Overview
  118. 8.20.3 Kyowa Kirin Anti-Parkinson's Disease Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  119. 8.20.4 Kyowa Kirin Anti-Parkinson's Disease Drugs Product Portfolio
  120. 8.20.5 Kyowa Kirin Recent Developments
  121. 8.21 GSK
  122. 8.21.1 GSK Company Information
  123. 8.21.2 GSK Business Overview
  124. 8.21.3 GSK Anti-Parkinson's Disease Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  125. 8.21.4 GSK Anti-Parkinson's Disease Drugs Product Portfolio
  126. 8.21.5 GSK Recent Developments
  127. 8.22 Endo International plc
  128. 8.22.1 Endo International plc Company Information
  129. 8.22.2 Endo International plc Business Overview
  130. 8.22.3 Endo International plc Anti-Parkinson's Disease Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  131. 8.22.4 Endo International plc Anti-Parkinson's Disease Drugs Product Portfolio
  132. 8.22.5 Endo International plc Recent Developments
  133. 8.23 Desitin Arzneimittel
  134. 8.23.1 Desitin Arzneimittel Company Information
  135. 8.23.2 Desitin Arzneimittel Business Overview
  136. 8.23.3 Desitin Arzneimittel Anti-Parkinson's Disease Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  137. 8.23.4 Desitin Arzneimittel Anti-Parkinson's Disease Drugs Product Portfolio
  138. 8.23.5 Desitin Arzneimittel Recent Developments
  139. 8.24 Boehringer Ingelheim
  140. 8.24.1 Boehringer Ingelheim Company Information
  141. 8.24.2 Boehringer Ingelheim Business Overview
  142. 8.24.3 Boehringer Ingelheim Anti-Parkinson's Disease Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  143. 8.24.4 Boehringer Ingelheim Anti-Parkinson's Disease Drugs Product Portfolio
  144. 8.24.5 Boehringer Ingelheim Recent Developments
  145. 8.25 Bausch Health
  146. 8.25.1 Bausch Health Company Information
  147. 8.25.2 Bausch Health Business Overview
  148. 8.25.3 Bausch Health Anti-Parkinson's Disease Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  149. 8.25.4 Bausch Health Anti-Parkinson's Disease Drugs Product Portfolio
  150. 8.25.5 Bausch Health Recent Developments
  151. 8.26 Astellas Pharma
  152. 8.26.1 Astellas Pharma Company Information
  153. 8.26.2 Astellas Pharma Business Overview
  154. 8.26.3 Astellas Pharma Anti-Parkinson's Disease Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  155. 8.26.4 Astellas Pharma Anti-Parkinson's Disease Drugs Product Portfolio
  156. 8.26.5 Astellas Pharma Recent Developments
  157. 8.27 Apokyn
  158. 8.27.1 Apokyn Company Information
  159. 8.27.2 Apokyn Business Overview
  160. 8.27.3 Apokyn Anti-Parkinson's Disease Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  161. 8.27.4 Apokyn Anti-Parkinson's Disease Drugs Product Portfolio
  162. 8.27.5 Apokyn Recent Developments
  163. 8.28 Akorn
  164. 8.28.1 Akorn Company Information
  165. 8.28.2 Akorn Business Overview
  166. 8.28.3 Akorn Anti-Parkinson's Disease Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  167. 8.28.4 Akorn Anti-Parkinson's Disease Drugs Product Portfolio
  168. 8.28.5 Akorn Recent Developments
  169. 8.29 Abbvie
  170. 8.29.1 Abbvie Company Information
  171. 8.29.2 Abbvie Business Overview
  172. 8.29.3 Abbvie Anti-Parkinson's Disease Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  173. 8.29.4 Abbvie Anti-Parkinson's Disease Drugs Product Portfolio
  174. 8.29.5 Abbvie Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Anti-Parkinson's Disease Drugs Value Chain Analysis
  2. 9.1.1 Anti-Parkinson's Disease Drugs Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Anti-Parkinson's Disease Drugs Production Mode & Process
  6. 9.2 Anti-Parkinson's Disease Drugs Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Anti-Parkinson's Disease Drugs Distributors
  9. 9.2.3 Anti-Parkinson's Disease Drugs Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst